retatrutide

Identity and computed properties

No PubChem compound record is pinned for this name, so no computed formula and no computed mass is printed here.

A PubChem name lookup for this compound answered HTTP 404 on 2026-09-16, and a text search of the PubChem compound index on the same date answered with ten records, seven of them titled as named impurities of this compound and one as its sodium salt. None is titled as the parent molecule, so no CID is pinned here and no formula or computed mass is printed.

The registered trial record

An intervention search of clinicaltrials.gov for the term retatrutide, read on 2026-09-17, returned 33 registered studies: 14 phase 1, 4 phase 2, 14 phase 3 and 1 recorded with no phase.

Eli Lilly and Company is lead sponsor on 32 of the 33 records. The remaining record names 1 other organization.

On the date read, the statuses those records carried were 21 completed, 9 active not recruiting and 2 recruiting, among others.

The earliest record the search returns is NCT03841630, first submitted 2019-02-13. That date is a floor, not an origin: earlier work may sit in the registry under a code number this search term does not match.

Registry counts measure registration, not knowledge.

The publication record

PubMed answered 185 records for the term "retatrutide"[tiab] OR "LY3437943"[tiab] on 2026-09-17. Of those, 8 carry a clinical-trial publication type, and 1 of those carries Clinical Trial, Phase III. 110 carry the publication type Review, which is other people reading the rest.

PubMed counts measure indexing, so work in venues it does not index is invisible to this figure. The term that produced it is printed above so it can be run again.

Regulatory status

A Drugs@FDA query on 2026-09-17 returned no application record for any of these 6 searches:

• openfda.generic_name:"retatrutide"
• openfda.substance_name:"retatrutide"
• openfda.brand_name:"retatrutide"
• openfda.generic_name:"ly3437943"
• openfda.substance_name:"ly3437943"
• openfda.brand_name:"ly3437943"

Every one of those searches answered HTTP 404 with NOT_FOUND on 2026-09-17, the date printed above them. The two names are the coined name the literature files this compound under and the developer's code number, which is the pair the pinned PubMed term also uses, and each is searched on the three openFDA name fields, generic name, substance name and brand name, which is why two names make six searches. Three lookups that do answer were run on the same date as a control, so an empty answer here is an absence in the database rather than a query shaped wrongly: semaglutide returned NDA 213051, tirzepatide returned NDA 215866 and NDA 217806, and bremelanotide returned NDA 210557. On the names checked, no United States application record stands for this compound. A name it may be filed under that is not listed above was not checked.

Other members of this class hold United States application records. A Drugs@FDA query on 2026-09-16 returned NDA 213051 for semaglutide, sponsor NOVO, and NDA 215866 and NDA 217806 for tirzepatide, sponsor ELI LILLY AND CO, and every product listed under all three is marked Prescription. So this class does have marketed articles a laboratory could reach for as comparators.

Findings, as published reports recorded them

humanThe phase 2 report in The Lancet, 12 August 2023, recorded least-squares mean changes from baseline in glycated haemoglobin at 24 weeks in all six of its dose groups of this compound: minus 0.43 percent in the 0.5 mg group, minus 1.39 percent and minus 1.30 percent in the two 4 mg groups, minus 1.99 percent and minus 1.88 percent in the two 8 mg groups, and minus 2.02 percent in the group escalated to 12 mg. The two comparison groups recorded minus 0.01 percent on placebo and minus 1.41 percent on 1.5 mg dulaglutide. The report states that every group of this compound except the 0.5 mg group separated from placebo at p below 0.0001, and that the 0.5 mg group did not separate from it.The Lancet · 2023-08-12 · DOI 10.1016/S0140-6736(23)01053-X · PMID 37385280 · read 2026-09-16

humanThe Lancet report recorded bodyweight at 36 weeks falling with dose: 3.19 percent in the 0.5 mg group, 7.92 percent in the 4 mg escalation group, 10.37 percent in the 4 mg group, 16.81 percent and 16.34 percent in the two 8 mg groups, and 16.94 percent in the group escalated to 12 mg, against 3.00 percent in the placebo group and 2.02 percent in the dulaglutide group. In plainer words, the three highest groups lost about a sixth of their bodyweight over 36 weeks and the placebo group lost about three percent. For doses of 4 mg and above the report gives the decrease as greater than placebo at p of 0.0017 for the 4 mg escalation group and below 0.0001 for the others.The Lancet · 2023-08-12 · DOI 10.1016/S0140-6736(23)01053-X · PMID 37385280 · read 2026-09-16

humanThat trial randomly assigned 281 participants across eight groups, 45 to placebo, 46 to 1.5 mg dulaglutide and 190 across the six groups given this compound, and 275 of them entered the efficacy analysis the figures above are drawn from, six having been enrolled inadvertently. Every one of the eight groups is printed above, so these are all the figures the abstract read here gives at those two endpoints rather than a selection from them.The Lancet · 2023-08-12 · PMID 37385280 · read 2026-09-16

Adverse events, as published reports recorded them

humanThe Lancet report recorded mild to moderate gastrointestinal adverse events, naming nausea, diarrhoea, vomiting and constipation, in 67 of the 190 participants across this compound's six groups, 35 percent, and gives the spread across those groups as a range: from 6 of 47 in the 0.5 mg group, 13 percent, to 12 of 24 in the 8 mg fast escalation group, 50 percent. Those two are the only groups the abstract read here gives a figure for, and the upper end of that range is not the highest dose in the trial, which was the group escalated to 12 mg. That abstract states that bodyweight decreased dose dependently with this compound at 36 weeks and states nothing of the kind about these events, so no relation between dose and these events is reported on this page. The comparison groups recorded 6 of 45 on placebo, 13 percent, and 16 of 46 on dulaglutide, 35 percent.The Lancet · 2023-08-12 · PMID 37385280 · read 2026-09-17

humanThe Lancet report states that there were no reports of severe hypoglycaemia and no deaths during that study.The Lancet · 2023-08-12 · PMID 37385280 · read 2026-09-16

Spontaneous report databases are not used on this page. A count of reports carries no denominator, so it cannot be read as a rate and is not printed as one.

Who it is not given to

No doctor prescribes this. There is no approved product under this name on the Food and Drug Administration record, read 2026-09-17, so there is no label naming who must avoid it and why.

Read this as missing information, not as a clear record. Nobody has published who is at risk, which is not the same as nobody being at risk.

What has not been published

• No PubChem compound record is pinned for this name, so no computed formula and no computed mass appears above.
• No receptor characterization has been compiled on this page. The phase 2 report read here describes the compound as an agonist at three named receptors in its own title, but no pharmacology paper was read for this entry, so nothing is printed under receptors.
• Nothing was reached on the salt form suppliers sell, and nothing on how material offered for research use compares with the article used in any registered study.

Where a line above says nothing has been compiled here, that is a gap in this publication's record. Where it says nothing is indexed or registered, that is a gap in the public record.

Sources

Registered study counts, phases, lead sponsors and first-submitted dates: the clinicaltrials.gov public API, one intervention search on the term printed above, read 2026-09-17. Indexed paper counts and publication types: PubMed, the term printed above and that term narrowed by publication type, read 2026-09-17. Application status: the Food and Drug Administration Drugs@FDA database through the agency public endpoint, read 2026-09-17.

The dates in the paragraph above are the dates those fetches ran, stamped in UTC. The dates in the list below are the dates a person read each record. The same record can carry both, a day apart, when a fetch ran after midnight UTC.

• The Lancet, 12 August 2023, PMID 37385280 read 2026-09-16
• Drugs@FDA application NDA 215866, tirzepatide read 2026-09-16